Description
LENCIVOG-GM3 is a potent, triple-action oral antidiabetic formulation by Ellanjey that combines Voglibose, Glimepiride and Metformin HCl (ER) – three complementary antihyperglycemic agents from different classes. This fixed-dose combination is indicated for the treatment of type 2 diabetes mellitus in patients whose blood glucose levels are not adequately controlled on dual therapy (such as metformin + glimepiride or metformin + voglibose).
Key Benefits:
-
Triple Mechanism of Action – Targets all three major defects of type 2 diabetes.
-
Voglibose – Delays carbohydrate absorption, reducing post-meal blood sugar spikes.
-
Glimepiride – Stimulates insulin release from the pancreas.
-
Metformin (ER) – Reduces liver glucose production & improves insulin sensitivity.
-
Comprehensive Glycemic Control – Lowers both fasting and postprandial (after-meal) glucose.
-
Extended Release Metformin – Smoother blood levels with fewer GI side effects.
FAQs:
1. What is unique about Voglibose compared to other diabetes medications?
Voglibose works in the gut by delaying carbohydrate absorption – directly targeting post-meal blood sugar spikes. Other oral agents work in the pancreas or liver, making voglibose complementary.
2. How should I take Lencivog-GM3 for best results?
Take it with the first bite of each main meal. Voglibose must be taken with food to work. The glimepiride and metformin components also absorb better with meals.
3. Does Lencivog-GM3 cause gas and bloating?
Voglibose commonly causes flatulence (gas) and bloating, especially in the first few weeks. These side effects are dose-related and often improve with continued use. Reducing dietary carbohydrates may help.
4. Is Lencivog-GM3 better than taking two separate diabetes medications?
Triple therapy (voglibose + glimepiride + metformin) targets postprandial glucose (voglibose), fasting glucose (glimepiride + metformin), and insulin resistance (metformin) – more comprehensive than dual therapy.
Call us 
Contact Us
